AusBio
Tracker
AusBio
Tracker
/
Company Directory
⌘K
Sign in
Browse
Watchlist
Compare
Companies
bookmark
Watchlist
compare_arrows
Compare
Pipeline
experiment
Trials
Capital & Insiders
account_balance
Capital
person
Directors
Signals
warning
Risk
description
News
More
feedback
Feedback
settings
Settings
dashboard
Dashboard
biotech
Companies
trending_up
Catalysts
experiment
Trials
more_horiz
More
/
NTI
Neurotech International
warning
data caveat
—
—
Companies
/
NTI
NI
NTI
Active
Tier 2
Neurotech International
ASX ↗
Data Health
Trials
3 of 5 active ·
stale enrollment
No cash data on file
Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—
Market Cap
—
Burn Rate
—
Shares Outstanding
—
Pipeline Assets
0
NTI
Latest
Director Tx
Shareholders
Announcements
Trials
Latest Insight
price-sensitive announcements & broker notes
Price-sensitive
Quarterly 4C
28 Apr 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Burn
$2.2M/q
·
OCF
$-2.2M
picture_as_pdf
View full announcement
3M Price
NTI.ASX
1W
1M
3M
6M
1Y
All
$0.012
+0.0%
1mo
Low $0.011
High $0.013
Pipeline Assets (0)
science
No pipeline data
Quarterly Cash Flow
payments
No cash flow data
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker data
Insider activity, holders, grants, publications
expand ›
collapse ‹
Director Transactions
1 transaction
Last 90d
No Activity
Buys
0
Sells
0
OPTIONS EXERCISE
Robert Maxwell Johnston
open_in_new
2026-04-24
Substantial Holders
(5%+ threshold)
1 notice
Clinical Trials
(7)
5 active
ClinicalTrials.gov ↗
Ph2/PHASE3
Not Yet Recruiting
NTI164
Placebo
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
RETT Syndrome With Proven MECP2 Mutation · Rett Syndrome
ENROL
40
no manual snapshots — enter via record_enrollment.py
NCT07257978 ↗
CT.gov
Start
2026-07
Primary end
2028-10
Ph3
Not Yet Recruiting
NTI164
Placebo
NTI164 in Autism Spectrum Disorder
Autism · Autism Spectrum Disorder · Autism Disorder
ENROL
98
no manual snapshots — enter via record_enrollment.py
NCT07257939 ↗
CT.gov
Start
2026-07
Primary end
2029-07
Ph1
Active Not Recruiting
schedule
Enrollment stale · 860d
NTI164
NTI164 Human PK Study
Healthy · Healthy Volunteer
ENROL
12
no manual snapshots — enter via record_enrollment.py
NCT06713447 ↗
CT.gov
Start
2024-02
Primary end
2025-06
Show 2 more active trials
expand_more
Show 2 completed / terminated trials
expand_more
Announcements
(5)
notification_important
PS
All announcements →
payments
Quarterly 4C
PS
auto_awesome
Quarterly Activities/Appendix 4C Cash Flow Report
28 Apr 2026
366KB
expand_more
person
Insider Trade
auto_awesome
Change of Director's Interest Notice
28 Apr 2026
274KB
expand_more
article
Other
Notification of cessation of securities - NTI
28 Apr 2026
12KB
article
substantial_holder
auto_awesome
Ceasing to be a substantial holder
23 Apr 2026
483KB
expand_more
article
Other
Neurotech to present at Ignite Investment Summit Hong Kong
12 Apr 2026
3767KB
CEASED
MAYBANK SECURITIES PTE. LTD.
4.52%
59,597,522 sh
2026-04-23
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet